

Research Article

New Biomarker in Chagas Disease: Extracellular Vesicles Isolated from Peripheral Blood in Chronic Chagas Disease Patients Modulate the Human Immune Response

Rafael Pedro Madeira ^{1,2}, Lavinia Maria Dal'Mas Romera,² Paula de Cássia Buck,³ Charles Mady,³ Barbara Maria Ianni,³ and Ana Claudia Torrecilhas ²

¹Disciplina de Infectologia, Departamento de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil

²Laboratório de Imunologia Celular e Bioquímica de Fungos e Protozoários, Departamento de Ciências Farmacêuticas, Universidade Federal de São Paulo (UNIFESP), Diadema, Brazil

³Unidade Clínica de Miocardiopatias, Instituto do Coração, Universidade de São Paulo (USP), São Paulo, Brazil

Correspondence should be addressed to Ana Claudia Torrecilhas; ana.torrecilhas@unifesp.br

Received 9 November 2020; Revised 21 December 2020; Accepted 30 December 2020; Published 12 January 2021

Academic Editor: Luiz Felipe Domingues Passero

Copyright © 2021 Rafael Pedro Madeira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chagas disease, a neglected tropical disease (NTD) caused by the flagellated protozoan *Trypanosoma cruzi* (*T. cruzi*), is a major public health problem. It was initially restricted to Latin America, but it is now expanding globally. Host and pathogen interactions are crucial in the establishment of disease, and since 1970, it has been known that eukaryotic cells release extracellular vesicles (EVs), which in turn have an important role in intercellular communication in physiological and pathological conditions. Our study proposed to characterize and compare circulating EVs isolated from the plasma of chronic Chagas disease (CCD) patients and controls. For this, peripheral blood was collected from patients and controls, and mononuclear cells (PBMCs) were isolated and stimulated with parasite EVs, showing that patient cells released fewer EVs than control cells. Then, after plasma separation followed by EV total shedding enrichment, the samples were subjected to ultracentrifugation to isolate the circulating EVs, which then had their size and concentration characterized by nanoparticle tracking analysis (NTA). This showed that patients had a lower concentration of circulating EVs while there were no differences in size, corroborating the *in vitro* data. Additionally, circulating EVs were incubated with THP-1 cells (macrophages) that, after the interaction, had their supernatant analyzed by ELISA for cytokine detection. In relation to their ability to induce cytokine production, the CCD patient EVs were able to induce a differential production of IFN- γ and IL-17 in relation to controls, with differences being more evident in earlier/less severe stages of the disease. In summary, a decreased concentration of circulating EVs associated with differential activation of the immunological system in patients with CCD is related to parasite persistence and the establishment of chronic disease. It is also a potential biomarker for monitoring disease progression.

1. Introduction

Trypanosoma cruzi is a protozoan parasite and the causative agent of Chagas disease (CD), also called American trypanosomiasis. CD is a systemic and chronic disease that is considered one of the 13 most Neglected Tropical Diseases (NTD) worldwide by the World Health Organization [1]. These diseases persist exclusively in the poorest and most marginalized populations, living without adequate sanitation and in close

contact with infected vectors and reservoirs. The disease affects 8 million people in Latin America from Mexico to Argentina, and there is a potential public health problem in the USA, as well as Europe and Asia, due to increasing immigration from endemic countries [2, 3].

In its chronic phase, the clinical presentations range from the absence of signs and symptoms (the indeterminate form) to a severe cardiac, digestive, or cardiodigestive burden with high morbidity and mortality [3–5]. The gold standard for

CCD diagnosis is a combination of two different serological assays, enzyme-linked immunosorbent assays (ELISA), hemagglutination inhibition assays (HAI), or indirect immunofluorescence (IIF), with the addition of a third test if the first two have discrepant results [6]. This combination approach is due to the reduced specificity of the tests based on the type of antigen used, which may lead to cross-reactivity with other parasitic diseases such as leishmaniasis [7]. There are still no available methodologies for the prognosis of confirmed chronic patients, although some studies using molecular and imaging approaches have shown some degree of correlation with the disease severity [8–10].

Once referred to as “platelet dust” by Wolf in 1967, extracellular vesicles (EVs) have now been extensively studied due to their role in intercellular communication and physiological and pathological conditions [11–13]. Their role in assessing disease progression as well as in establishing a prognosis suggests a potential use for them as biomarkers in noncommunicable diseases, such as cancer, but also in infectious diseases such as latent tuberculosis infection [14–16].

In a previous work by our group, we showed that *T. cruzi* trypomastigotes derived from infected mammalian cells released vesicles into the medium and that EVs of different sizes were associated with both the parasite membrane and the culture medium ([17]; [18]). These EVs carry glycoproteins are responsible for cell activation via TLR2, and it modulates the host innate immune response and increases the number of cell infections and intracellular parasites [19, 20]. The major glycoproteins from parasite surface, such as TS/gp85 glycoproteins and mucins, were found in EVs release by infective trypomastigote forms of *T. cruzi*. The mucins are the major surface glycoproteins from *T. cruzi* cell surface and are rich in O-linked α -galactosyl (α Gal) epitope-containing oligosaccharides [21]. These α -Gal epitopes are the major target of lytic anti- α Gal antibodies, which are the predominant IgG during Chagas’ disease and have the ability to control parasitic infection [21]. Furthermore, the addition of sialic acid residues confers a protection to the parasite against the anti- α Gal antibodies [22]. In fact, a proteomic analysis of this EVs isolated from trypomastigotes forms show that about 60% of the hits correspond to proteins of the 85 K Daltons family (gp85/TS) and mucins of the protozoa parasite [20]. Those glycoproteins are involved in the parasite host interaction and invasion by the parasite ([23–27]; [18, 28]). EVs contain virulence factors involved in pathogenesis and immunopathology, suggesting their ability to modulate host immune responses and inflammation.

In vivo, EVs increase the number of amastigote nests in heart tissue and carry virulence factors that are important for pathogenesis ([18–20, 29]).

The applications of EVs in clinical therapy have rapidly advanced in the past decade. The main challenges in clinical investigation are to promote the use of EVs in clinical trials and during the follow-up of many inflammatory and infectious diseases, as there is still no biomarker for infectious disease progression. Since EVs were demonstrated to be important for the development of heart parasitism and inflammation in animal models of infection, we proposed

to characterize the peripheral blood circulating population of EVs in CCD patients as well as their immunomodulatory capacity *in vitro*.

2. Materials and Methods

2.1. Ethics Statement. All of the experiments in this work were approved by the Federal University of São Paulo Ethics Committee in Research, CEP/UNIFESP (CAAE: 70749317.2.0000.5505), and samples from both patient and healthy controls were only collected after individuals agreed to participate and signing a written informed consent form.

2.2. Participants. The study included 70 individuals, 40 chronic Chagas disease patients and 30 healthy controls, selected from two university outpatient clinics (infected) and laboratory staff (noninfected) between January 2019 and May 2019. All patients, despite being in different disease stages, had a positive serological diagnosis for Chagas disease using ELISA and IIF. The patients were further divided into groups according to disease stage, degree of cardiac burden, and functional classification by New York Heart Association parameters as described in Table 1.

2.3. Obtaining and Isolating EVs Released by Trypanosoma Cruzi. *T. cruzi* culture (Y strain) was maintained by infection of green monkey kidney LLC-MK2 epithelial cells (ATCC, Manassas, VA) in Dulbecco’s modified eagle (DME) medium supplemented with 10% fetal bovine serum (FBS) at 37°C, under 5% CO₂ atmosphere, as described elsewhere [29]. Total *T. cruzi* shed vesicles were obtained from the culture medium supernatant of tissue culture cell-derived trypomastigotes (TCTs), which were harvested 5 to 9 days after the infection of LLC-MK2 cells. Parasites were counted, centrifuged (15 min, 1,500–2,000g, 10°C), and resuspended in DME medium supplemented with 5% FBS, at a concentration of 1×10^9 parasites/mL of medium. After incubation for 2–3 h at 37°C, under 5% CO₂ atmosphere, trypomastigotes were removed by centrifugation (10 min, 3000 g, 10°C), and the supernatant containing the total shed material was filtered through a 0.45 μ m cartridge [20, 29].

2.4. Fractionation of *T. cruzi* Vesicles. The total shed material was 2-fold diluted with 200 mM ammonium acetate (pH 6.5) and loaded onto a Sepharose CL-4B column (1 \times 40 cm, GE Healthcare, Piscataway, NJ) preequilibrated with 100 mM ammonium acetate (pH 6.5). The column was eluted with the equilibration buffer, in a flow rate of 0.2 mL/min using a peristaltic pump (GE Healthcare). Fractions ($N = 80$) of 1 mL were collected and then screened by chemiluminescent enzyme-linked immunosorbent assay (CL-ELISA) as described elsewhere [20], using anti-*T. cruzi* membrane polyclonal antibody (mouse) or anti-Alpha Gal purified from sera of chronic Chagasic patients (human Ch anti- α Gal), as described [21]. The most reactive fractions being pooled and concentrated in a vacuum centrifuge and then resuspended in filtered PBS for further analysis by nanoparticle tracking analysis (NTA) as previously described [20, 29, 30].

TABLE 1: Patients' and controls' baseline and clinical characteristics. Chronic Chagas disease patients (CCD; $n = 40$) and controls (CTRL; $n = 30$).

		Chronic Chagas disease (CCD)	Healthy controls (CTRL)
Sex	Male	17	10
	Female	23	20
Age	<20	0	1
	20-39	1	27
	40-59	18	2
	60-80	20	0
	>80	1	0
Clinical stage of cardiac burden	Indeterminate	10	—
	ECG alteration	15	—
	ECG alteration + ventricular dysfunction	15	—
NYHA functional classification	I	28	—
	II	8	—
	IV	4	—
		160	60

ECG: electrocardiogram; NYHA: New York Heart Association.

2.5. Blood Collection and Sample Preparation. Blood from the CCD samples was collected in lithium heparin for peripheral blood mononuclear cell (PBMC) isolation in a Ficoll-Paque (GE Healthcare) density gradient according to the manufacturer's instructions. Additionally, blood collected in sodium EDTA tubes was left at ambient temperature for 4 h and then incubated overnight at 4°C for plasma separation, which was used as the starting material for the isolation of circulating EVs.

2.6. Isolation of EVs from CCD Patient Plasma. After plasma separation from the blood, it was submitted to centrifugation at 100,000g for 1 h in a Thermo Scientific™ Sorvall™ WX100 Ultra Centrifuge using a fixed angle rotor (Thermo Scientific™ T-8100 Fixed Angle Rotor). The pellets were resuspended in filtered PBS (0.2 μm syringe filter) and then analyzed by NTA.

2.7. Scanning Electron Microscopy (SEM). PBMCs, after incubation for 24 and 48 h with and without EVs isolated from parasites, were fixed in a 2.5% glutaraldehyde solution, post-fixed with osmium tetroxide, treated with tannic acid, and dehydrated with ethanol [29]. The samples were observed in a field emission FEI Quanta 250 FEG scanning electron microscope (FEI, OR, USA).

2.8. PBMC-Parasite EV Interaction Assay. Following isolation, 1×10^5 PBMCs were seeded on 24-well plates and incubated for 24 h in culture medium. After 24 h, the cells were washed with PBS and then incubated with parasite EVs at a 1:100 (cell:EV) ratio, parasite extract (obtained from freeze-thawing and filtering an equivalent of 10^8 parasites), and culture medium for another 24 h at 37°C and 5% CO₂. Supernatants were centrifuged for 10 minutes at 750g and then analyzed by NTA.

2.9. Nanoparticle Tracking Analysis (NTA). EVs isolated from parasites and samples from patients were diluted in filtered PBS and then loaded into the NanoSight NS300 equipment (Malvern Panalytical) coupled to an sCMOS camera at a 532 nm wavelength, camera level set to auto, threshold and focus set manually to optimize readings as per the manufacturer's instructions. Readings were taken in triplicate for 30 seconds at 25 frames per second, and the data were analyzed using Nanoparticle Tracking Analysis software (NTA version 3.2 Dev Build 3.2.16).

2.10. Immunological Assays. THP-1 cells (ATCC® TIB-202™ Cell Type: monocyte) (10^7 cells) were differentiated with macrophages. Fifty ng/mL phorbol 12-myristate 13-acetate was primed with 10 ng/mL human recombinant interferon-gamma (IFN-γ, GenScript). The cells were then incubated with EVs isolated from plasma patients in a 1:100 (cell:EV) ratio. All incubations were performed at 37°C in 5% CO₂ for 24 h. Supernatants were collected for cytokine assays. Culture medium alone was used as a negative control.

2.11. Cytokine Measurements. For the ELISA cytokine detection, supernatants were collected, and cytokines were determined using Human Cytokine assay kits (Human DuoSet ELISA, R&D Systems) according to the manufacturer's specifications. The cytokines TNF-α, IFN-γ, IL-4, IL-5, IL-6, IL-10, IL12p70, and IL-17 were assessed and, when detected in the supernatant, had their concentration measured and compared to controls and between subgroups of patients.

2.12. Statistical Analysis. All data sets were assessed using GraphPad Prism 7.0 software (GraphPad Software Inc., San Diego, USA) and Orange (University of Ljubljana, Slovenia). As appropriate, Spearman's correlation, unpaired *t*-tests with Welch's correction, and ordinary one-way ANOVA followed by Dunnett's multiple comparisons test were performed, and




FIGURE 1: CCD patients' clinical data analysis. Frequency of patients by the stage of cardiac burden in relation to the NYHA functional classification.




FIGURE 2: Scanning electron microscopy (SEM) of CCD PBMCs releasing EVs after 24 and 48 h of parasite EV stimulus. 24 h control in (a, b), 48 h control in (e, f), 24 h parasite EV stimulus in (c, d), and 48 h parasite EV stimulus in (g, h).

the results are presented as the means \pm 95% confidence intervals.

3. Results

3.1. Patient Distribution among Subgroups and Analysis of Clinical Data. Our cohort of patients was evenly distributed between male and female individuals as well as disease stage and degree of cardiac burden, with the majority (39 out of 40) of patients being over 40 years old and in NYHA class I (Table 1). Additionally, there was a correlation between a higher degree of cardiac burden and NYHA functional classification (Figure 1). Full clinical data from the patients are presented in Supplementary Table 1.

3.2. PBMC Purification from Chronic Chagas Disease Patients Releases Fewer EVs Than from Healthy Individuals. PBMCs isolated from chronic Chagas disease patients' blood can constitutively release EVs, as shown by scanning electron microscopy (Figure 2). When stimulated with *T. cruzi* extract or *T. cruzi* EVs, PBMC EVs presented a similar size dispersion but a smaller mean particle size than healthy individuals (Figure 3, top and center). For their mean concentration, even though they were larger in size, they were fewer in quantity when compared to healthy individuals (Figure 3, bottom).

3.3. Chronic Chagas Disease Patients Have Fewer Total Circulating EVs in Plasma Than Healthy Individuals (Control). After isolation from plasma, nanoparticle tracking analysis revealed that patients with chronic Chagas disease had a lower concentration of total circulating EVs when compared to healthy individuals, corroborating the observed results from peripheral blood mononuclear cells (Figure 4(a)). When analyzing the frequencies of the concentration values throughout subgroups of patients, it was observed that reduced concentrations of circulating EVs were associated with alterations in cardiac clinical parameters (Figure 4(b)), but this phenomenon was not observed when assessing EV size (Figure 4(c)).

3.4. EVs from Chronic Chagas Disease Patients Induce Differential Cytokine Production and Release from THP-1 Cells (Macrophages). After EV stimulation, differentiated and activated THP-1 cells (macrophages) exhibited differential production and release of cytokines in the supernatant. In general, cells that interacted with chronic Chagas patient EVs exhibited a higher production of IFN- γ but a lower production of IL-17 (Figure 5). When the data were analyzed based on the different patient subgroups, IFN- γ differential production was maintained throughout every subset analyzed, while IL-17 only presented a tendency toward a reduction in patient samples. Taking into consideration the clinical stage of cardiac burden, IFN- γ production is higher due to




FIGURE 3: Continued.





FIGURE 3: Comparison of EV profiles from CCD and CTRL PBMCs after a 24 h incubation. Concentration/size distribution (top), mean size \pm 95%CI (center) and mean concentration \pm 95%CI (bottom) after (a) culture medium (* $p = 0.0326$ and **** $p < 0.0001$), (b) *T. cruzi* extract (** $p = 0.0003$ and **** $p = 0.0002$), or (c) *T. cruzi* EV stimuli (**** $p < 0.0001$).

interaction with EVs from patients with the indeterminate form and decreases as the severity of cardiac burden increases (Figure 6(a)), a phenomenon that is clearly observed when the frequencies of each subgroup are plotted against the IFN- γ concentration (Figure 6(b)). On the other hand, IL-17 production after EV stimuli showed no significant difference, with only a tendency toward lower levels of this cytokine in the patients (Figures 6(c) and 6(d)). When the data were analyzed based on the New York Heart Association (NYHA) Functional Classification, only EVs from patients included in Class I induced higher IFN- γ production (Figure 7(a)) and lower IL-17 production (Figure 7(c)) than


the control EVs, as was also seen on the overlapping curves of frequency by cytokine concentration (Figures 7(b) and 7(d), respectively). In addition to the clinical parameters, age showed a positive correlation with IFN- γ production (Figure 8(a)) and a negative correlation with IL-17 (Figure 8(b)), but in neither case was sex relevant to the results obtained.

4. Discussion

Extracellular vesicles are released from a wide array of cells ranging from prokaryotic organisms to higher eukaryotes



(a)



- Control ($\mu = 521203333.33, \sigma = 369134052.87$)
- Electrocardiogram alteration ($\mu = 521203333.33, \sigma = 369134052.87$)
- Electrocardiogram alteration and ventricular dysfunction ($\mu = 473606666.67, \sigma = 345704410.28$)
- Indeterminate ($\mu = 611272000, \sigma = 523468182.28$)

(b)

FIGURE 4: Continued.




FIGURE 4: Comparison of circulating EV profiles in CCD patients in relation to CTRL. (a) Concentration (particles/mL) \times size (nm) profile. (b) Frequency of EV concentration among different degrees of cardiac burden. (c) Frequency of EV size among different stages of cardiac burden.




FIGURE 5: Cytokine production by THP-1 cells (macrophages) quantified in the supernatant by ELISA after 24 h of stimulation with CCD or CTRL EVs. (* $p = 0.0438$ and *** $p = 0.0002$).

and are found in virtually all body fluids in humans [13, 31, 32]. They have important roles in intercellular signaling during physiological processes, such as in kidney physiology, where urinary EVs may play a role in the renin-angiotensin system by carrying angiotensin-converting enzyme and being able to interact with cells in the renal tubule lumen [33]. Another important example of EVs helping to maintain homeostasis is in modulating chemotaxis, signaling, and the proliferation of hematopoietic cells by platelet-derived microparticles [34].

Due to the many different cells circulating in blood, we first wanted to assess whether the mononuclear cell EV-releasing behavior in chronic Chagas disease patients was compatible with what was observed in healthy individuals. Peripheral blood mononuclear cells from chronic Chagas patients released a lower quantity of EVs than cells from healthy individuals when cultivated *in vitro*, and this phenomenon was also observed when quantifying EVs directly from peripheral blood plasma.

The alteration of body fluid EV concentrations in pathological states has been described in both infectious and inflammatory models [35, 36]. In patients with periodontitis, there is a higher concentration of EVs in gingival crevicular fluid, which correlates with the clinical inflammatory periodontal parameters [37]. A similar phenomenon is observed in patients with human African trypanosomiasis, where late stage patients have a higher concentration of EVs in cerebrospinal fluid when compared to early and intermediate stages, with these EVs also showing different functional properties such as altering astrocyte protein expression *in vitro* [38]. In our study, as the EV concentration in patients was lower than that in controls, we hypothesized that this might have led to a loss of function in the human immune response, which in turn contributed to infection persistence and severity, as in a previously described *in vitro* model of *Pseudomonas aeruginosa* infection where the infected cells released fewer EVs that, in turn, carried less CCL4 mRNA, contributing to a less effective immune response [39].




FIGURE 6: Cytokine production by THP-1 cells (macrophages) quantified in the supernatant by ELISA after 24 h of stimulation with CCD or CTRL EVs among patients grouped based on the clinical stage of the cardiac burden and controls. (a) IFN- γ concentration in pg/mL ($*p = 0.0420$, $**p = 0.0291$, and $***p = 0.0118$). (b) Frequency of IFN- γ concentration values. (c) IL-17 concentration in pg/mL. (d) Frequency of IL-17 concentration values.

To assess the impact of circulating EVs on the human immune response, despite their decreased number in chronic Chagas patients, we incubated macrophage (THP-1) cells, which were previously differentiated and activated, with EVs and quantified an array of cytokines in the culture supernatant. The importance of studying cytokines in Chagas disease can be exemplified by polymorphisms in genes related to Th1-type T cell differentiation playing a role in genetic susceptibility to chronic Chagas cardiomyopathy [40]. In our model, we observed that while most cytokines analyzed could

not be detected or showed no differences among the groups, both IFN- γ and IL-17 presented a differential profile when comparing chronic Chagas patients and healthy controls.

We observed that in samples from patients, circulating EVs induced a higher production of IFN- γ , corroborating data available from an in vivo chronic model of benznidazole treatments where the treated mice had fewer IFN- γ -producing cells as well as an improvement in electrocardiographic alterations. Additionally, circulating IFN- γ was positively correlated with the cardiac inflammatory process and




FIGURE 7: Cytokine production by THP-1 cells (macrophages) quantified in the supernatant by ELISA after 24 h of stimulation with CCD or CTRL EVs among patients grouped based on NYHA functional classification and controls. (a) IFN- γ concentration in pg/mL (**** $p = 0.0001$). (b) Frequency of IFN- γ concentration values (0: CTRL). (c) IL-17 concentration in pg/mL (* $p = 0.0125$). (d) Frequency of IL-17 concentration values (0: CTRL).


parasite burden [41, 42]. In contrast to IFN- γ , IL-17 production was diminished after stimulation with patient EVs, which in murine models is associated with compromised parasite control and a reduction of the response magnitude and survival of CD8⁺ T cells [43]. This combination of augmented IFN- γ and reduced IL-17 may play an important role in parasite persistence in chronic disease as well as tissue damage in target organs due to continuous inflammatory signaling.

In an attempt to evaluate whether the alterations in circulating EV concentration and subsequent immune activation would be associated with Chagas disease chronification and progression, we stratified our cohort of patients by sex, age, degree of cardiac burden, and functional classification.


Sex can be an important factor in inflammation pathophysiology. In athletes who suffered a concussion, while men have a positive correlation of IFN- γ levels with the severity of their symptoms, women have a negative correlation of IFN- γ levels and symptom severity [44]. However,

apart from a slight difference in healthy individuals, sex was not a factor that could interfere with IFN- γ production after stimulus with EVs from chronic Chagas disease patients.

While sex represented no interfering factor with IFN- γ production, age proved itself a much more complex factor. During aging, a process called immunosenescence takes place and it is characterized by a decrease in the acute inflammatory response combined with a persistent low-grade inflammatory profile that may lead to a higher risk of infection development as well as participate in the pathogenesis of chronic noncommunicable diseases such as osteoporosis, rheumatoid arthritis, and coronary heart disease [45–47]. After incubation with circulating EVs from patients, macrophages produced more IFN- γ than healthy controls. Another point to take into consideration is that almost all of the patients were older than the controls, so a combination of both age and infection might be responsible for the increase in IFN- γ levels and the establishment of a basal proinflammatory environment, which in turn could be related to



(a)



(b)

FIGURE 8: Correlation of age (X axis), cytokine production by THP-1 cells (macrophages) quantified in the supernatant by ELISA after 24 h of stimulation with CCD or CTRL EVs (Y axis) and sex (●: female; X: male). (a) IFN- γ ($r = 0.34$). (b) IL-17 ($r = -0.15$).

cardiac tissue damage characteristic of chronic symptomatic Chagas disease [48, 49].

IFN- γ production represents a major factor in Chagas disease pathogenesis. When we compared different degrees of cardiac damage, clinically assessed by electrocardiography

(ECG), we observed that only EVs from patients in the indeterminate stage or with only ECG alterations were able to induce IFN- γ production, as EVs from patients with ECG alterations combined with ventricular dysfunction could not. This might suggest that an increase in IFN- γ production,

and consequently more inflammation, is crucial in the establishment of chronic disease more than in the final stages, where the severity of symptoms is more due to a loss of organ function [50, 51].

In addition to the cardiac burden, the overall effects on its function could also be related to immunological EV-mediated signaling [52, 53]. Corroborating the data derived from patients grouped by ECG, when we looked at the loss of cardiac function, we observed that IFN- γ production was also increased when using EVs from patients with no loss of function, validating our hypothesis that a proinflammatory environment is a key point in the establishment of chronic disease. Another important point is that in functionally normal patients, their EVs also led to a decrease in IL-17. A follow-up study in school-aged children with Chagas disease found that higher IL-17A levels were associated with the persistence of infection after treatment with benznidazole, suggesting this cytokine could be a possible biomarker for nonresponse to treatment and the persistence of infection [54]. However, when we analyzed our data under this hypothesis, in contrast to what was previously described, EVs from chronic patients with no cardiac function loss induced a lower production of IL-17, suggesting that in patients who did not receive benznidazole treatment, this cytokine might have another role, even a protective one.

The observed important role of EVs in Chagas disease pathogenesis and chronic disease combined with their altered quantity when compared to healthy individuals suggests EVs are a possible biomarker for disease progression. Even though other situations may alter the concentration of circulating EVs, their differential effect on target cells suggests a composition unlike that seen for healthy individuals' vesicles. Proteomics studies using primary murine or immortalized human cells infected with parasites such as *Plasmodium yoelii* and *Trypanosoma cruzi* demonstrated that EVs released from infected cells carry parasite molecules as well their own cargo, but none showed this phenomenon using circulating EVs or EVs from patients [55, 56].

In the case of Chagas disease, some highly expressed parasite molecules are important for infection, such as the virulence factors *trans*-sialidase and cruzipain [57]. These molecules are able to induce a humoral immune response that can be detected and used for diagnostics and treatment monitoring, even though cross-reactivity with other infections also exists [57–59]. Considering the demonstrated importance of EVs in the modulation of the immune response of infection and their altered concentration in circulation, EVs present themselves as promising candidates for biomarkers of disease progression in Chagas disease.

Data Availability

Data are available on request.

Conflicts of Interest

No potential conflict of interest was reported by the authors.

Authors' Contributions

RPM, BMI, and ACT conceived and designed the experiments. RPM, LMDR, PCB, and ACT performed most of the experiments. RPM, BMI, and ACT wrote the manuscript. RPM, BMI, CM, and ACT contributed to the final manuscript. All of the authors reviewed the manuscript.

Acknowledgments

We thank all colleagues from the Laboratório de Imunologia Celular e Bioquímica de fungos e protozoários (LICBfp), Departamento de Ciências Farmacêuticas, UNIFESP, who provided helpful technical advice and expertise that greatly assisted the research. This work was supported by FAPESP Regular (2016/01917-3) and CNPq Universal (408186/2018-6) grants and a CAPES doctoral fellowship (Financial Code 001).

Supplementary Materials

Supplementary Table 1: full clinical data from patients and controls. (*Supplementary Materials*)

References

- [1] P. J. Hotez, D. H. Molyneux, A. Fenwick et al., "Control of neglected tropical diseases," *The New England Journal of Medicine*, vol. 357, pp. 1018–1027, 2007.
- [2] J. R. Coura and P. A. Vias, "Chagas disease: a new worldwide challenge," *Nature*, vol. 465, pp. S6–S7, 2010.
- [3] A. Rassi, A. Rassi, and J. A. Marin-Neto, "Chagas disease," *Lancet*, vol. 375, pp. 1388–1402, 2010.
- [4] N. G. Echavarría, L. E. Echeverría, M. Stewart, C. Gallego, and C. Saldarriaga, "Chagas disease: chronic Chagas cardiomyopathy," *Current Problems in Cardiology*, vol. 1, no. article 100507, 2020.
- [5] L. E. Echeverría, R. Marcus, G. Novick et al., "WHF IASC roadmap on Chagas disease," *Global Heart*, vol. 15, p. 26, 2020.
- [6] Organización Panamericana de la Salud, *Guía para el diagnóstico y el tratamiento de la enfermedad de Chagas*, 2018.
- [7] Z. C. Caballero, O. E. Sousa, W. P. Marques, A. Saez-Alquezar, and E. S. Umezawa, "Evaluation of serological tests to identify *Trypanosoma cruzi* infection in humans and determine cross-reactivity with *Trypanosoma rangeli* and *Leishmania* spp," *Clinical and Vaccine Immunology*, vol. 14, pp. 1045–1049, 2007.
- [8] T. F. Cianciulli, M. C. Saccheri, A. Papantoniou et al., "Use of tissue Doppler imaging for the early detection of myocardial dysfunction in patients with the indeterminate form of Chagas disease," *Revista da Sociedade Brasileira de Medicina Tropical*, vol. 53, 2020.
- [9] N. Cortes-Serra, I. Losada-Galvan, M. J. Pinazo, C. Fernandez-Becerra, J. Gascon, and J. Alonso-Padilla, "State-of-the-art in host-derived biomarkers of Chagas disease prognosis and early evaluation of anti-*Trypanosoma cruzi* treatment response," *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1866, article 165758, 2020.
- [10] C. K. Nonaka, B. R. Cavalcante, A. C. Alcántara et al., "Circulating miRNAs as potential biomarkers associated with cardiac remodeling and fibrosis in Chagas disease cardiomyopathy," *International Journal of Molecular Sciences*, vol. 20, p. 4064, 2019.

- [11] J. H. Campos, R. P. Soares, K. Ribeiro, A. Cronemberger Andrade, W. L. Batista, and A. C. Torrecilhas, "Extracellular vesicles: role in inflammatory responses and potential uses in vaccination in cancer and infectious diseases," *Journal of Immunology Research*, vol. 2015, 14 pages, 2015.
- [12] A. C. Torrecilhas, R. I. Schumacher, M. J. M. Alves, and W. Colli, "Vesicles as carriers of virulence factors in parasitic protozoan diseases," *Microbes and Infection*, vol. 14, pp. 1465–1474, 2012.
- [13] M. Yáñez-Mó, P. R. Siljander, Z. Andreu et al., "Biological properties of extracellular vesicles and their physiological functions," *Journal of extracellular vesicles*, vol. 4, article 27066, 2015.
- [14] J. J. Castellano, R. M. Marrades, L. Molins et al., "Extracellular vesicle lincRNA-p21 expression in tumor-draining pulmonary vein defines prognosis in NSCLC and modulates endothelial cell behavior," *Cancers*, vol. 12, p. 734, 2020.
- [15] E. Le Rhun, J. Seoane, M. Salzet, R. Soffietti, and M. Weller, "Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system," *Cancer Letters*, vol. 480, pp. 24–28, 2020.
- [16] C. Mehaffy, N. A. Kruh-Garcia, B. Graham et al., "Identification of *Mycobacterium tuberculosis* peptides in serum extracellular vesicles from persons with latent tuberculosis infection," *Journal of Clinical Microbiology*, vol. 58, 2020.
- [17] M. F. Gonçalves, E. S. Umezawa, A. M. Katzin et al., "Trypanosoma cruzi : shedding of surface membrane vesicles antigens as," *Experimental Parasitology*, vol. 53, pp. 43–53, 1991.
- [18] A. C. Torrecilhas, R. R. Tonelli, W. R. Pavanelli et al., "Trypanosoma cruzi: parasite shed vesicles increase heart parasitism and generate an intense inflammatory response," *Microbes and Infection*, vol. 11, pp. 29–39, 2009.
- [19] A. Cronemberger-Andrade, P. Xander, R. P. Soares et al., "Trypanosoma cruzi-infected human macrophages shed proinflammatory extracellular vesicles that enhance host-cell invasion via toll-like receptor 2," *Frontiers in Cellular and Infection Microbiology*, vol. 10, 2020.
- [20] K. S. Ribeiro, C. I. Vasconcellos, R. P. Soares et al., "Proteomic analysis reveals different composition of extracellular vesicles released by two Trypanosoma cruzi strains associated with their distinct interaction with host cells," *Journal of extracellular vesicles*, vol. 7, 2018.
- [21] I. C. Almeida, M. A. J. Ferguson, S. Schenkman, and L. R. Travassos, "Lytic anti- α -galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi," *The Biochemical Journal*, vol. 304, pp. 793–802, 1994.
- [22] V. L. Pereira-Chioccola, A. Acosta-Serrano, I. C. De Almeida et al., "Mucin-like molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes from killing by human anti- α -galactosyl antibodies," *Journal of cell science*, vol. 113, pp. 1299–1307, 2000.
- [23] R. Giordano, D. L. Fouts, D. Tewari, W. Colli, J. E. Manning, and M. J. M. Alves, "Cloning of a surface membrane glycoprotein specific for the infective form of Trypanosoma cruzi having adhesive properties to laminin," *The Journal of Biological Chemistry*, vol. 274, pp. 3461–3468, 1999.
- [24] M. H. Magdesian, R. Giordano, H. Ulrich et al., "Infection by Trypanosoma cruzi: identification of a parasite ligand and its host cell receptor," *The Journal of Biological Chemistry*, vol. 276, pp. 19382–19389, 2001.
- [25] K. A. Norris, B. Bradt, N. R. Cooper, and M. So, "Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor," *Journal of Immunology*, vol. 147, 1991.
- [26] S. Schenkman, D. Eichinger, M. E. A. Pereira, and V. Nussenzweig, "Structural and functional properties of Trypanosoma trans-sialidase," *Annual Review of Microbiology*, vol. 48, pp. 499–523, 1994.
- [27] S. Schenkman, M. S. Jiang, G. W. Hart, and V. Nussenzweig, "A novel cell surface trans-sialidase of trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells," *Cell*, vol. 65, pp. 1117–1125, 1991.
- [28] A. C. Torrecilhas, R. P. Soares, S. Schenkman, C. Fernández-Prada, and M. Olivier, "Extracellular vesicles in trypanosomatids: host cell communication," *Frontiers in Cellular and Infection Microbiology*, vol. 10, p. 750, 2020.
- [29] P. M. Nogueira, K. Ribeiro, A. C. Silveira et al., "Vesicles from different Trypanosoma cruzi strains trigger differential innate and chronic immune responses," *Journal of extracellular vesicles*, vol. 4, article 28734, 2015.
- [30] C. Théry, K. W. Witwer, E. Aikawa et al., "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines," *Journal of extracellular vesicles*, vol. 7, 2018.
- [31] M. Colombo, G. Raposo, and C. Théry, "Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles," *Annual Review of Cell and Developmental Biology*, vol. 30, pp. 255–289, 2014.
- [32] M. Tkach and C. Théry, "Communication by extracellular vesicles: where we are and where we need to go," *Cell*, vol. 164, pp. 1226–1232, 2016.
- [33] T. Pisitkun, R. F. Shen, and M. A. Knepper, "Identification and proteomic profiling of exosomes in human urine," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, pp. 13368–13373, 2004.
- [34] M. Baj-Krzyworzeka, M. Majka, D. Pratico et al., "Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells," *Experimental Hematology*, vol. 30, pp. 450–459, 2002.
- [35] F. Shiri, B. K. Gale, H. Sant, G. T. Bardi, J. L. Hood, and K. E. Petersen, "Characterization of human glioblastoma versus normal plasma-derived extracellular vesicles preisolated by differential centrifugation using cyclical electrical field-flow fractionation," *Analytical Chemistry*, vol. 92, no. 14, pp. 9866–9876, 2020.
- [36] A. Ł. Zadka, A. Piotrowska, and A. Opalińska, "Comparative analysis of exosome markers and extracellular vesicles between colorectal cancer and cancer-associated normal colonic mucosa," *Polish Archives of Internal Medicine*, vol. 4, 2020.
- [37] A. Chaparro Padilla, L. Weber Aracena, O. Realini Fuentes et al., "Molecular signatures of extracellular vesicles in oral fluids of periodontitis patients," *Oral Diseases*, vol. 26, pp. 1318–1325, 2020.
- [38] V. Dozio, V. Lejon, D. Mumba Ngoyi, P. Büscher, J. C. Sanchez, and N. Tiberti, "Cerebrospinal fluid-derived microvesicles from sleeping sickness patients alter protein expression in human astrocytes," *Frontiers in Cellular and Infection Microbiology*, vol. 9, 2019.

- [39] L. B. Jones, S. Kumar, C. R. Bell et al., "Effects of *Pseudomonas aeruginosa* on microglial-derived extracellular vesicle biogenesis and composition," *Pathogens*, vol. 8, 2019.
- [40] A. F. Frade-Barros, B. M. Ianni, S. Cabantous et al., "Polymorphisms in genes affecting interferon- γ production and Th1 T cell differentiation are associated with progression to Chagas disease cardiomyopathy," *Frontiers in Immunology*, vol. 11, pp. 1–12, 2020.
- [41] M. S. Rial, E. C. Arrúa, M. A. Natale et al., "Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of *Trypanosoma cruzi* Nicaragua infection in mice," *The Journal of Antimicrobial Chemotherapy*, vol. 75, pp. 1906–1916, 2020.
- [42] B. C. de Carvalho, M. Wesley, A. Moraes et al., "Correlation of parasite burden, kDNA integration, autoreactive antibodies, and cytokine pattern in the pathophysiology of Chagas disease," *Frontiers in Microbiology*, vol. 10, p. 1856, 2019.
- [43] J. Tosello Boari, C. L. Araujo Furlan, F. Fiocca Vernengo et al., "IL-17RA-signaling modulates CD8⁺ T cell survival and exhaustion during *Trypanosoma cruzi* infection," *Frontiers in Immunology*, vol. 9, p. 2347, 2018.
- [44] A. P. Di Battista, N. Churchill, S. G. Rhind, D. Richards, and M. G. Hutchison, "The relationship between symptom burden and systemic inflammation differs between male and female athletes following concussion," *BMC Immunology*, vol. 21, no. 1, article 11, 2020.
- [45] C. Franceschi, M. Bonafè, S. Valensin et al., "Inflamm-aging: an evolutionary perspective on immunosenescence," *Annals of the New York Academy of Sciences*, vol. 908, pp. 244–254, 2000.
- [46] G. R. Mundy, "Osteoporosis and inflammation," *Nutrition Reviews*, vol. 65, pp. S147–S151, 2008.
- [47] P. Sarzi-Puttini, F. Atzeni, A. Doria, L. Iaccarino, and M. Turiel, "Tumor necrosis factor- α , biologic agents and cardiovascular risk," *Lupus*, vol. 14, pp. 780–784, 2005.
- [48] L. Koelman, O. Pivovarova-Ramich, A. F. H. Pfeiffer, T. Grune, and K. Aleksandrova, "Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation," *Immunity & Ageing*, vol. 16, 2019.
- [49] M. Meuser-Batista, N. Vacani-Martins, C. M. Cascabulho, D. G. Beghini, and A. Henriques-Pons, "In the presence of *Trypanosoma cruzi* antigens, activated peripheral T lymphocytes retained in the liver induce a proinflammatory phenotypic and functional shift in intrahepatic T lymphocyte," *Journal of Leukocyte Biology*, vol. 107, pp. 695–706, 2020.
- [50] É. Santos and L. Menezes Falcão, "Chagas cardiomyopathy and heart failure: from epidemiology to treatment," *Revista Portuguesa de Cardiologia*, vol. 39, pp. 279–289, 2020.
- [51] L. E. Villanueva-Lizama, J. V. Cruz-Chan, L. Versteeg et al., "TLR4 agonist protects against *Trypanosoma cruzi* acute lethal infection by decreasing cardiac parasite burdens," *Parasite Immunology*, vol. 42, 2020.
- [52] R. Almeida Paiva, T. Martins-Marques, K. Jesus et al., "Ischaemia alters the effects of cardiomyocyte-derived extracellular vesicles on macrophage activation," *Journal of Cellular and Molecular Medicine*, vol. 23, pp. 1137–1151, 2019.
- [53] J. Zhang, X. Cui, J. Guo et al., "Small but significant: insights and new perspectives of exosomes in cardiovascular disease," *Journal of Cellular and Molecular Medicine*, vol. 24, 2020.
- [54] C. Vásquez Velásquez, G. Russomando, E. E. Espínola et al., "IL-17A, a possible biomarker for the evaluation of treatment response in *Trypanosoma cruzi* infected children: a 12-months follow-up study in Bolivia," *PLoS Neglected Tropical Diseases*, vol. 13, article e0007715, 2019.
- [55] L. Martin-Jaular, E. S. Nakayasu, M. Ferrer, I. C. Almeida, and H. A. del Portillo, "Exosomes from *Plasmodium yoelii*-infected reticulocytes protect mice from lethal infections," *PLoS One*, vol. 6, article e26588, 2011.
- [56] M. I. Ramirez, P. Deolindo, I. J. de Messias-Reason et al., "Dynamic flux of microvesicles modulate parasite-host cell interaction of *Trypanosoma cruzi* in eukaryotic cells," *Cellular Microbiology*, vol. 19, article e12672, 2017.
- [57] C. Y. Chain, D. E. Pires Souto, M. L. Sbaraglini et al., "*Trypanosoma cruzi* virulence factors for the diagnosis of Chagas' disease," *ACS infectious diseases*, vol. 5, pp. 1813–1819, 2019.
- [58] V. L. Pereira-Chioccola, A. A. Fragata-Filho, A. M. De Aparecida Levy, M. M. Rodrigues, and S. Schenkman, "Enzyme-linked immunoassay using recombinant trans-sialidase of *Trypanosoma cruzi* can be employed for monitoring of patients with Chagas' disease after drug treatment," *Clinical and Diagnostic Laboratory Immunology*, vol. 10, pp. 826–830, 2003.
- [59] E. S. Saba, L. Gueyffier, M. L. Dichtel-Danjoy et al., "Anti-*Trypanosoma cruzi* cross-reactive antibodies detected at high rate in non-exposed individuals living in non-endemic regions: seroprevalence and association to other viral serologies," *PLoS One*, vol. 8, article e74493, 2013.